Feature|Articles|September 16, 2025

6 Things You Need to Know About MFN Drug Pricing | MJH Life Sciences Webinar

Author(s)Peter Wehrwein, Managing Editor

A half-dozen takeaways from an MJH Life Sciences webinar on the Trump administration's push for most-favored nation drug pricing

Last week MJH Life Scienceshosted the first installment of its three-part webinar series, “The Most Favored Nation Mandate: What the President’s Drug Pricing Push Means for Pharma, Payers, and Patients.” The roundtable discussion featured Brian Corvino, principal and global market access practice leader at Deloitte US; Neal Masia, Ph.D., co-founder and CEO of EntityRisk, Inc., and founder of Health Capital Group, LLC; Ali Pashazadeh, founder, chairman and CEO of Treehill Partners; and George Van Antwerp, MBA, senior vice president of product innovation and strategic planning at Prime Therapeutics.